dual gip/glp-1 receptor agonist GLP-1/GIP agonists mechanism of action Frontiers | GLP-1/GIP dual agonist

[DOI] [PMC free article] [PubMed] [Google Scholar] [206].Nordisk N., Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide, 2018

Another limitation of the studies was the use of different comparators ranging from placebo controls to other medications for T2DM (including insulin), which have different effects on bone tissue and were included in only one group, misleading the interpretation

Sauzet, O., Carvajal, A., Escudero, A., Molokhia, M

SURPASS-2 was an open-label, 40-week, Phase 3 clinical trial.1879 patients enrolled and received tirzepatide at a dose of 5 mg, 10 mg, or 15 mg, or semaglutide at a dose of 1 mg

The TAG-MS trial reads out in roughly two years

doi: 10.1016/j.physbeh.2015.06.013